
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …
Boehringer Ingelheim has moved a step closer to getting its investigational treatment nintedanib approved in Europe for a potentially fatal …

